Clinical trials, biomarkers, microbiome, genetics, AI, basic science, and emerging IBD research.
Page 51 of 65 · 3097 articles
Researchers and clinicians are exploring cGAS/STING as a novel immune pathway linked to mucosal barrier function and inflammation in UC. Modulators of this pathway could become future targeted treatments, so patients and...
Identifies macrophage-linked genes (CCL3, CCL4, JUNB) that are strongly upregulated in ulcerative colitis and may help explain immune-cell remodeling in the colon. These genes could serve as biomarkers or starting points...
This trial tests whether people with UC in deep remission can safely stop JAK inhibitor therapy — potentially reducing long-term exposure and associated safety concerns while preserving disease control and quality of...
This Phase 2a trial tested a new investigational drug, tulisokibart, in people with moderately to severely active Crohn’s disease who have not done well on prior therapies — so patients and clinicians watching new...
The study will prospectively evaluate how often dysplasia occurs, how lesions look and behave after endoscopic resection, and what factors predict local or distant recurrence—information that could change surveillance...
The systems view could explain limits of single-cytokine therapies and point toward multi-layer, precision approaches that better match a patient’s specific immune, genetic, and microbial context.
The editorial outlines treatment strategies that could affect whether a person with ASUC avoids colectomy, highlights the importance of getting adequate infliximab exposure, and summarizes emerging drug classes that may...
Exercise is a low-cost, accessible intervention that may improve quality of life and reduce symptoms in people with IBD. This pooled analysis suggests some exercise types — especially regular continuous aerobic exercise...
The study links ER stress and defective autophagy to increased claudin-2 and tight-junction dysfunction—mechanisms relevant to barrier loss in IBD. Targeting this pathway could eventually inform therapies to preserve...
Detecting Crohn’s recurrence after bowel surgery is important because recurrence can occur without symptoms. A reliable non-invasive test like intestinal ultrasound could reduce the need for repeated colonoscopies and...
For people with moderate–severe Crohn’s disease who failed anti‑TNF drugs, this trial suggests risankizumab may achieve higher corticosteroid‑free clinical and endoscopic remission than ustekinumab, which could mean...
A natural compound (diosgenin) reduced disease signs and inflammatory markers in a mouse model of ulcerative colitis, suggesting a possible anti-inflammatory mechanism that could inform future preclinical research.
Many people with IBD who achieve remission ask about reducing or stopping medication. This review summarises current evidence and highlights that withdrawal carries substantial relapse risk and that decisions should be...
Automated, sequence-robust MRI measures could help standardize detection and localization of perianal anoperineal lesions in Crohn’s disease, which is relevant for diagnosis and management of perianal complications.
A majority of surveyed IBD patients who use marijuana reported better quality of life and relief from symptoms such as nausea, joint pain, insomnia and anxiety — findings of interest to people seeking symptom management...
The review examines whether removing the appendix could change the course of ulcerative colitis — a potential surgical option that might lower colectomy or hospitalization risk in some scenarios but also carries...
The article points to plant-derived compounds with anti-inflammatory and antioxidant actions that may be relevant to colitis mechanisms, which could be of interest to patients and clinicians following experimental or...
The study suggests Artemisia rupestris extract can reduce inflammation, repair the intestinal barrier, and shift the gut microbiota and metabolites in a mouse colitis model — pathways that are important in IBD. These...
An LTE Phase 2 study offers longer-term safety monitoring and continued access to investigational long-acting antibody drugs for people who completed or met escape criteria in the parent SKYLINE-UC trial; that can matter...
This trial is testing a new experimental oral therapy (BRS201) aimed at reducing hydrogen sulfide–related metabolites in people with mild ulcerative colitis. If successful, the drug could represent a novel, non-biologic...
This trial tests etrasimod (an S1P receptor modulator) specifically in older adults with active ulcerative colitis — a group often underrepresented in IBD trials. Results could inform safety and short-term remission...
AIEC is linked to IBD pathogenesis but is defined by lab assays rather than clear genetic markers. This paper presents a practical assay to detect cell invasion even when isolates are resistant to gentamicin, which could...
The study investigates how components of exclusive enteral nutrition (EEN), particularly transforming growth factor‑β (TGF‑β), may help restore intestinal barrier function after colitis. That could help explain why EEN...
A treatable-traits approach could help tailor IBD care to each patient by targeting specific biological, comorbid, and psychosocial drivers of disease and quality-of-life impairment, potentially improving how we choose...
People with IBD may be interested because the review describes a probiotic (L. plantarum) and synbiotic approaches that could influence gut inflammation, barrier function, and microbiota—areas directly relevant to IBD...
Targeting STING may reduce inflammatory signaling that contributes to ulcerative colitis; a safer, more potent STING inhibitor could become a new therapeutic approach if later-stage studies confirm benefit and safety.
This research links molecular subtypes of ulcerative colitis to infliximab (anti-TNF) response using an interpretable machine-learning method, which could help identify which patients are more or less likely to respond...
AI could help identify dietary patterns, predict which patients might benefit from specific nutrition approaches, and provide personalized nutrition support — potentially improving inflammation and gut microbiome...
This research describes a new nanoparticle/hydrogel delivery system that reduced inflammation and helped restore the intestinal barrier in mouse models of ulcerative colitis. It suggests a potential future therapeutic...
This preclinical study reports a new pH-sensitive liposomal formulation that increased intestinal delivery and anti-inflammatory effects of roxadustat in animal models of colitis, which could be relevant to future oral...
This study identifies a specific probiotic–commensal interaction that improved colitis in mice and points to a metabolite (phosphatidylcholine) and metabolic pathway that might help repair the gut barrier — a pathway...
Oxidative stress may help explain some biological drivers of inflammation in Crohn’s disease and ulcerative colitis and could become a target for biomarkers or therapies in the future. Right now, the evidence is...
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Chinese Journal of...
Patients and clinicians often ask whether herbal formulas or plant compounds can help IBD. This preclinical study identifies quercetin and the PI3K–Akt pathway as potential mechanisms, which may guide future research...
The study suggests JAK and TYK2 inhibitors can directly change epithelial inflammatory signaling and proliferation in UC, which may be relevant to healing of the gut lining and how different drugs work beyond immune...
People with ulcerative colitis may be interested because synbiotic approaches aim to change the gut microbiome and intestinal barrier and therefore could become a future therapeutic option or adjunct. The paper...
The paper describes a potential new anti-inflammatory/hepatoprotective candidate (a cyanobacterium extract) tested in mouse models of liver injury and IBD — early-stage research that could guide future studies but is not...
The paper suggests that loss of microbial bile acid transformations in IBD reduces activation of the TGR5 receptor, and that lower TGR5 bioactivity correlates with higher inflammatory activity — a potential mechanism...
The study links tissue and blood molecular changes to UC severity, suggesting candidate mechanisms (fibrogenesis, neutrophil activation) that could lead to biomarkers or new therapeutic targets. Understanding severity...
The study identifies a plant-derived compound that reduced inflammation and liver injury in a mouse model of ulcerative colitis and ties its effects to both JAK2/STAT1 inhibition and changes in the gut microbiota—two...
This review pools available pediatric data showing ustekinumab can induce and maintain remission after anti‑TNF failure, offering a treatment option for children with refractory IBD. Results are most robust for Crohn’s...
Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease and Research and clinical trials. The original article is from hmpgloballearningnetwork.com.
Earlier use of advanced therapies and less steroid exposure could affect long-term outcomes and side-effect risk for people with newly diagnosed IBD. The study also identifies lower use of advanced therapies among...
If the appendix is a significant source of harmful IgG antibodies in ulcerative colitis, that could help explain why appendectomy sometimes reduces UC risk or severity and might influence future therapies targeting...
This study suggests that older-onset IBD is managed more conservatively and experiences fewer extraintestinal manifestations. Patients and clinicians should be aware that age can influence treatment choices and that...
The study suggests nanoplastic particles can alter intestinal barrier function, goblet cells, mucin secretion, and inflammation-related gene expression in models with genetic susceptibility to Crohn’s disease.
Researchers are exploring new anti‑inflammatory compounds derived from food sources; this study reports a krill‑derived selenium‑chelated peptide that reduced inflammation in cells and improved outcomes in a mouse...
Researchers are exploring targeted nanodelivery of miR-497 to reduce oxidative stress and shift immune cells toward tissue-repairing states — a novel preclinical strategy that could eventually lead to new treatments for...
